ATENT 8.1 2313-1450, on the date shown below.

Dated:

| Calculate | Calculate

Docket No.: SUPP-P05-008

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Plant Application of:

Crabtree et al.

Application No.: 10/040430

Confirmation No.:

Filed: January 7, 2002

Art Unit: 1634

For:

NF-AT POLYPEPTIDES AND

POLYNUCLEOTIDES AND SCREENING METHODS FOR IMMUNOSUPPRESSIVE

AGENTS

Examiner: C. Myers

January 28, 2004

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c).

A copy of each reference on PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

9358341_1.DOC

Application No.: 10/040430 Docket No.: SUPP-P05-008

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. SUPP-P05-008. A duplicate copy of this paper is enclosed.

Dated: January 28, 2004

Respectfully submitted,

Gloria Fuentes

Registration No.: 47,580 ROPES & GRAY LLP One International Place Boston, Massachusetts 02110-2624

(617) 951-7000 (617) 951-7050 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/040430	
				Filing Date	January 7, 2002	
				First Named Inventor	Gerald R. Crabtree	
				Art Unit	1634	
				Examiner Name	C. Myers	
Sheet	1	of	1	Attorney Docket Number	SUPP-P05-008	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attracted. Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	CA	EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation", <i>Reports</i> , December 22, 1989, pp. 1617-1619.					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	 Date	
Signature	Considered	
0250247 4 00	 	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.